Research programme: brain cancer therapeutics - CombinatoRx
Latest Information Update: 22 Sep 2010
At a glance
- Originator CombinatoRx
- Developer Zalicus
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Glioblastoma
Most Recent Events
- 01 Oct 2004 Preclinical trials in Glioblastoma in USA (unspecified route)